PentostatinIrreversible adenosine deaminase inhibitor CAS# 53910-25-1 |
- CGS 21680
Catalog No.:BCC1475
CAS No.:120225-54-9
- CGS 21680 HCl
Catalog No.:BCC4316
CAS No.:124431-80-7
- Valsartan
Catalog No.:BCC5017
CAS No.:137862-53-4
- Istradefylline (KW-6002)
Catalog No.:BCC3798
CAS No.:155270-99-8
- Ticlopidine HCl
Catalog No.:BCC4973
CAS No.:53885-35-1
- Tozadenant
Catalog No.:BCC2011
CAS No.:870070-55-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 53910-25-1 | SDF | Download SDF |
| PubChem ID | 439693 | Appearance | Powder |
| Formula | C11H16N4O4 | M.Wt | 268.27 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Deoxycoformycin | ||
| Solubility | DMSO : ≥ 50 mg/mL (186.38 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol | ||
| SMILES | C1C(C(OC1N2C=NC3=C2NC=NCC3O)CO)O | ||
| Standard InChIKey | FPVKHBSQESCIEP-JQCXWYLXSA-N | ||
| Standard InChI | InChI=1S/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)/t6-,7+,8+,9+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Irreversible inhibitor of adenosine deaminase (Ki = 2.5 pM). Anticancer agent. |
Pentostatin Dilution Calculator
Pentostatin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.7276 mL | 18.6379 mL | 37.2759 mL | 74.5518 mL | 93.1897 mL |
| 5 mM | 0.7455 mL | 3.7276 mL | 7.4552 mL | 14.9104 mL | 18.6379 mL |
| 10 mM | 0.3728 mL | 1.8638 mL | 3.7276 mL | 7.4552 mL | 9.319 mL |
| 50 mM | 0.0746 mL | 0.3728 mL | 0.7455 mL | 1.491 mL | 1.8638 mL |
| 100 mM | 0.0373 mL | 0.1864 mL | 0.3728 mL | 0.7455 mL | 0.9319 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Pentostatin is a nucleoside analog and also is a potent inhibitor of adenosine deaminase. It has a broad spectrum of immunomodulatory activities. [1] The capacity of this purine analogue to inhibit proliferation and to induce apoptosis of T-cells in combination with its mild toxicity results in the approach to use pentostatin in steroid-refractory aGvHD.[2]
Chronic graft-versus-host disease (GVHD) is the main cause of late morbidity and non–relapse mortality after hematopoietic stem cell transplantation (HSCT).
Most relevant to GVHD, Pentostatin causes marked reduction of CD4 and CD8 cells. There is also significant B-cell depletion with reduction of IgG levels.13 This should allow it to affect GVHD at the cellular level and thus has the potential to address the many manifestations of chronic GVHD. Pentostatin is found to be active in a phase 1 study in refractory acute GVHD. A phase 2 study of pentostatin in heavily pretreated patients (median age, 33 years; median of 4 prior regimens) with chronic GVHD showed a 55% objective response rate in 58 patients.
In comparison with other treatment options, pentostatin has some favourable characteristics and its effect is sustainable and the majority of responding patients survived. The costs for pentostatin are relatively low and the toxicity is moderate.
References:
[1]David A. Jacobsohn, Andrew L. Gilman, Alfred Rademaker et al. Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study. BLOOD, 12 NOVEMBER 2009 _ VOLUME 114, NUMBER 20
[2] Stefan A. Klein1, Gesine Bug2, Sabine Mousset2 et al. Long term outcome of patients with steroid-refractory acute intestinal graft versus host disease after treatment with pentostatin. British Journal of Haematology, 154, 141–155
- Nb-Feruloyltryptamine
Catalog No.:BCN3899
CAS No.:53905-13-8
- Tranilast
Catalog No.:BCC2514
CAS No.:53902-12-8
- Allicin
Catalog No.:BCN2347
CAS No.:539-86-6
- Perillen
Catalog No.:BCN6527
CAS No.:539-52-6
- Hordenine
Catalog No.:BCN1424
CAS No.:539-15-1
- Ticlopidine HCl
Catalog No.:BCC4973
CAS No.:53885-35-1
- Desoxo-narchinol A
Catalog No.:BCN7636
CAS No.:53859-06-6
- Caboxine A
Catalog No.:BCN5715
CAS No.:53851-13-1
- 8-Prenylnaringenin
Catalog No.:BCN2998
CAS No.:53846-50-7
- Flavaprin
Catalog No.:BCN5714
CAS No.:53846-49-4
- 3-(beta-D-Glucopyranosyloxy)-2-hydroxybenzoic acid methyl ester
Catalog No.:BCN7734
CAS No.:53827-68-2
- Trifloroside
Catalog No.:BCN6915
CAS No.:53823-10-2
- (+)-Anabasine hydrochloride
Catalog No.:BCC7219
CAS No.:53912-89-3
- Hederagenin 28-O-beta-D-glucopyranosyl ester
Catalog No.:BCN1423
CAS No.:53931-25-2
- Deoxyarbutin
Catalog No.:BCC4774
CAS No.:53936-56-4
- Crotalarine
Catalog No.:BCN2076
CAS No.:53937-97-6
- Euparone
Catalog No.:BCN7204
CAS No.:53947-86-7
- Apterin
Catalog No.:BCN3910
CAS No.:53947-89-0
- Corylin
Catalog No.:BCN5716
CAS No.:53947-92-5
- Aristolactam AII
Catalog No.:BCN3924
CAS No.:53948-07-5
- Aristolactam BII
Catalog No.:BCN5717
CAS No.:53948-09-7
- Aristolactam BIII
Catalog No.:BCN5718
CAS No.:53948-10-0
- Glycyrrhizic acid ammonium salt
Catalog No.:BCN5943
CAS No.:53956-04-0
- Ginsenoside F1
Catalog No.:BCN1244
CAS No.:53963-43-2
Pentostatin, Cyclophosphamide and Rituximab (PCR) Regimen.[Pubmed:28057947]
Hosp Pharm. 2016 Dec;51(11):888-893.
The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr., President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, email: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net. The information presented in this review is based on published data and clinical expertise and includes information not included in the product labeling. Incorporation of such published data provides a more robust assessment of the drugs and assists pharmacists in evaluation of orders for off-label use of these agents.
High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses.[Pubmed:26071480]
Clin Cancer Res. 2015 Oct 1;21(19):4312-20.
PURPOSE: We hypothesized that lymphoid-selective host conditioning and subsequent adoptive transfer of sirolimus-resistant allogeneic T cells (T-Rapa), when combined with high-dose sirolimus drug therapy in vivo, would safely achieve antitumor effects while avoiding GVHD. EXPERIMENTAL DESIGN: Patients (n = 10) with metastatic renal cell carcinoma (RCC) were accrued because this disease is relatively refractory to high-dose conditioning yet may respond to high-dose sirolimus. A 21-day outpatient regimen of weekly Pentostatin (P; 4 mg/m(2)/dose) combined with daily, dose-adjusted cyclophosphamide (C;
Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas.[Pubmed:25828695]
Br J Haematol. 2015 Jun;169(6):814-23.
We conducted a prospective phase II trial of Pentostatin, cyclophosphamide and rituximab as initial therapy for patients with previously untreated advanced stage low-grade or indolent B-cell lymphomas (iNHLs). Of 83 evaluable patients, 91.6% attained an overall response and 86.8% a complete or unconfirmed complete response. The 3-year progression-free survival (PFS) and overall survival rates were 73% and 93%, respectively. The 3-year PFS rate was significantly different for different diagnoses (P = 0.01): 83% [95% confidence interval (CI): 0.72, 0.96] for follicular lymphomas, 73% (95% CI: 0.54, 1.0) for marginal zone lymphomas and 61% (95% CI: 0.46, 0.81) for small lymphocytic lymphomas. The most common adverse events were haematological. Of 509 cycles of chemotherapy administered, grade 3 or 4 neutropenia was reported in 68 cycles (13% of cycles administered) and most frequently occurred during cycles 4-6. This is the first report demonstrating the effectiveness of Pentostatin, cyclophosphamide and rituximab in patients with previously untreated iNHLs, including those over 60 years of age.
